Bone Therapeutics
-
Financial
Bone Therapeutics announces 2018 full year results
Gosselies, Belgium, 1 March 2019, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Financial
Bone Therapeutics Business Update for Third Quarter 2018
Gosselies, Belgium, 7 November 2018, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More » -
Biologics
Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis
Gosselies, Belgium, 17 October 2018, 6 pm CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company…
Read More » -
Biologics
Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study
Gosselies, Belgium, 14 September 2018, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company…
Read More » -
Financial
Bone Therapeutics Business Update for First Quarter 2018
Gosselies, Belgium, 4 May 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Biologics
Bone Therapeutics SA completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®
Gosselies, Belgium, 19 February 2018, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Biologics
Bone Therapeutics SA : Business Update for Third Quarter 2017
Gosselies, Belgium, 9 November 2017, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Biologics
Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
Gosselies, Belgium, 31 August 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris:BOTHE), the bone cell therapy company addressing…
Read More » -
Biologics
Bone Therapeutics Strengthens Board of Directors
Gosselies, Belgium, 3 July 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Biologics
Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
Gosselies, Belgium, 26 June 2017; 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More » -
Biologics
Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
Gosselies, Belgium, 29 May 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company…
Read More » -
Biologics
Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
March 06, 2017 GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE) (Euronext Brussels and Paris: BOTHE), the bone cell therapy…
Read More » -
Biologics
Bone Therapeutics Expands Its Delayed-Union Program with ALLOB® into Multiple Fractures
GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field…
Read More » -
Biologics
Bone Therapeutics: ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair…
Read More » -
Financial
Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News: BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of…
Read More »